Castle Biosciences announces latest AGA guideline on NDBE

Castle Biosciences announced that the latest American Gastroenterological Association, AGA, clinical practice guideline recognized that not all patients with non-dysplastic BE, NDBE, are at low risk of developing esophageal cancer. The guideline acknowledges the role that tissue-based biomarkers, including the tissue systems pathology test, can play in identifying high-risk NDBE patients who may benefit from endoscopic eradication therapy (EET) to prevent disease progression. In the recently published AGA guideline, the expert panel of authors acknowledge the role that tissue-based biomarkers can play in stratifying the large pool of patients with NDBE to help identity those at high risk of progression for consideration of treatment with EET at an early, precancerous stage.